JINARC TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

TOLVAPTAN; TOLVAPTAN

Disponibbli minn:

OTSUKA PHARMACEUTICAL CO LTD

Kodiċi ATC:

C03XA01

INN (Isem Internazzjonali):

TOLVAPTAN

Dożaġġ:

15MG; 15MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

TOLVAPTAN 15MG; TOLVAPTAN 15MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

VASOPRESSIN ANTAGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0256610004; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2019-08-16

Karatteristiċi tal-prodott

_JINARC_
®
_ Product Monograph _
_Page 1 of 43_
PRODUCT MONOGRAPH
Pr
JINARC
®
(tolvaptan)
Tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg
Vasopressin V
2
-receptor Antagonist
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan 101-8535
Imported and distributed by
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, Quebec
H4S 2C9
Date of Preparation:
February 23, 2015
Date of Revision:
October 23, 2019
Submission Control No: 228294
_ _
_JINARC_
®
_ Product Monograph _
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
17
OVERDOSAGE
................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 22
STORAGE AND STABILITY
.........................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 25
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
.........................................................................
26
CLINICAL TRIALS
........